Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: SIGA is a bio-defense company focused on the discovery, development, and commercialization of products against biological warfare agents (e.g., smallpox, Arenaviruses) and novel anti-infectives. The company has no commercial products and relies on government contracts, grants, and equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenues | $1,925,777 | $1,982,540 |
| Operating Expenses | $4,866,205 | $3,970,434 |
| Operating Loss | $(2,940,428) | $(1,987,894) |
| Net Loss | $(6,884,501) | $(858,304) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.03) |
| Cash and Cash Equivalents (End of Period) | $1,563,660 | $5,090,173 |
| Net Cash Used in Operating Activities | $(2,051,959) | $(1,610,046) |
| Net Cash Provided by Financing Activities | $1,294,100 | $25,935 |
| Total Assets | $7,406,263 | $8,797,300 |
| Total Liabilities | $13,767,299 | $7,242,701 |
| Stockholders' Equity | $(6,361,036) | $1,554,599 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 2.9% ($57,000) compared to Q1 2008. This was primarily due to a $385,000 decline in revenue from Arenavirus programs, partially offset by $270,000 in revenue from a new $55 million NIH contract for ST-246 development.
- Significant Increase in Net Loss: Net loss widened significantly from $858,304 in Q1 2008 to $6.9 million in Q1 2009. The primary driver was a $3.9 million loss recorded due to the increase in the fair value of common stock warrants (derivative liability), compared to a $1.1 million gain in the prior year.
- Operating Expenses: Total operating expenses increased by $896,000 (22.6%). Selling, general, and administrative (SG&A) expenses more than doubled (105% increase) to $2.1 million, driven by $690,000 in increased legal/litigation support, $216,000 in stock-based compensation, and $136,000 in severance costs. R&D expenses decreased slightly by 4.9%.
- Liquidity Position: Cash and cash equivalents decreased by $758,000 during the quarter. Total liabilities increased by $6.5 million, largely due to the reclassification and fair value adjustment of warrants to liabilities under new accounting standards (EITF 07-05).
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash balances, combined with proceeds from an investment commitment with MacAndrews & Forbes (M&F), continuing government grants, and anticipated new contracts, will support operations beyond the next twelve months. The company expects to continue incurring operating losses.
- Financing Activity: In a subsequent event (April 2009), the company exercised its right to receive $1.5 million from M&F under an extended investment agreement. The investment period was extended through June 19, 2010.
- Government Contracts: The company is responding to a Request for Proposal (RFP) from BARDA for the procurement of 1.7 million courses of smallpox medical countermeasures, with potential awards expected in September 2009.
- Legal Contingencies: PharmAthene, Inc. is pursuing litigation seeking a license agreement for ST-246 and unspecified damages. The company believes a loss cannot be reasonably estimated at this time but asserts meritorious defenses.
- Accounting Changes: Adoption of EITF 07-05 on January 1, 2009, required the reclassification of certain warrants as liabilities, resulting in a $2.7 million adjustment to accumulated deficit and subsequent fair value fluctuations impacting net income.
Investor Verification Checklist
- Derivative Liability Volatility: Verify the sensitivity of the $9.6 million warrant liability to changes in stock price and volatility, as this significantly impacts reported net loss.
- Cash Runway: Confirm the sufficiency of the $1.6 million cash balance against the $2.1 million quarterly burn rate, considering the timing of the $1.5 million M&F funding.
- BARDA RFP Status: Monitor the outcome of the BARDA smallpox procurement solicitation, which is critical for future revenue stability.
- PharmAthene Litigation: Track developments in the PharmAthene lawsuit, as an adverse ruling could impact the company's ability to commercialize its lead drug candidate, ST-246.
- Government Funding Reliance: Assess the risk associated with the company's heavy reliance on NIH and DoD contracts, which comprised nearly 100% of revenue in Q1 2009.